INOVIO PHARMACEUTICALS, INC. (INO) Current Ratio
- Current ratio · latest quarter: Value 1.00×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.00× | Current assets / current liabilities. $39.91M ÷ $39.92M ≈ 1.00× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 39.91M USD | Assets, Current |
| Current obligations | 39.92M USD | Liabilities, Current |
| Cash and equivalents | 31.53M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $39.91M | $39.92M | $31.53M | (m) | (m) | (m) | (m) | (m) | 1.00× |
| 2026-03-31 | $39.44M | $37.92M | $26.27M | (m) | (m) | (m) | (m) | (m) | 1.04× |
| 2025-12-31 | $61.12M | $43.67M | $44.27M | (m) | (m) | (m) | (m) | (m) | 1.40× |
| 2025-09-30 | $55.18M | $69.82M | $36.57M | (m) | $978.59K | (m) | (m) | (m) | 0.79× |
| 2025-06-30 | $52.70M | $31.71M | $24.35M | (m) | $840.31K | (m) | (m) | (m) | 1.66× |
| 2025-03-31 | $71.89M | $27.33M | $39.92M | (m) | $1.31M | (m) | (m) | (m) | 2.63× |
| 2024-12-31 | $97.83M | $35.33M | $65.81M | (m) | $1.20M | (m) | (m) | (m) | 2.77× |
| 2024-09-30 | $91.28M | $23.50M | $21.69M | (m) | $1.86M | (m) | (m) | (m) | 3.88× |
| 2024-06-30 | $117.56M | $26.40M | $34.39M | (m) | $1.77M | (m) | (m) | (m) | 4.45× |
| 2024-03-31 | $111.68M | $23.40M | $19.60M | (m) | $2.55M | (m) | (m) | (m) | 4.77× |
| 2023-12-31 | $153.11M | $42.57M | $14.31M | (m) | $2.41M | (m) | (m) | (m) | 3.60× |
| 2023-09-30 | $174.77M | $43.71M | $18.80M | (m) | (m) | (m) | (m) | (m) | 4.00× |
| 2023-06-30 | $203.28M | $51.93M | $52.71M | (m) | (m) | (m) | (m) | (m) | 3.91× |
| 2023-03-31 | $233.90M | $55.15M | $28.24M | (m) | $73.30K | (m) | (m) | (m) | 4.24× |
| 2022-12-31 | $315.24M | $96.87M | $46.33M | (m) | (m) | (m) | (m) | (m) | 3.25× |
| 2022-09-30 | $350.21M | $94.91M | $21.99M | (m) | $2.44M | (m) | (m) | (m) | 3.69× |
| 2022-06-30 | $416.19M | $131.06M | $41.10M | (m) | $4.48M | (m) | (m) | (m) | 3.18× |
| 2022-03-31 | $399.91M | $59.36M | $59.01M | (m) | $4.00M | (m) | (m) | (m) | 6.74× |
| 2021-12-31 | $448.44M | $65.74M | $71.14M | (m) | $5.47M | (m) | (m) | (m) | 6.82× |
| 2021-09-30 | $487.40M | $51.38M | $67.94M | (m) | $4.77M | (m) | (m) | (m) | 9.49× |
| 2021-06-30 | $542.42M | $51.75M | $58.93M | (m) | $13.13M | (m) | (m) | (m) | 10.48× |
| 2021-03-31 | $588.43M | $41.54M | $83.63M | (m) | $9.91M | (m) | (m) | (m) | 14.17× |
| 2020-12-31 | $471.17M | $41.71M | $250.73M | (m) | $18.56M | (m) | (m) | (m) | 11.30× |
| 2020-09-30 | $377.06M | $41.26M | $178.70M | (m) | $7.69M | (m) | (m) | (m) | 9.14× |
| 2020-06-30 | $382.06M | $37.98M | $215.43M | (m) | $3.51M | (m) | (m) | (m) | 10.06× |
| 2020-03-31 | $275.54M | $32.29M | $158.45M | (m) | $641.64K | (m) | (m) | (m) | 8.53× |
| 2019-12-31 | $94.20M | $31.99M | $22.20M | (m) | $700.07K | (m) | (m) | (m) | 2.94× |
| 2019-09-30 | $98.81M | $19.55M | $15.85M | (m) | $776.29K | (m) | (m) | (m) | 5.06× |
| 2019-06-30 | $110.51M | $24.08M | $19.74M | (m) | $130.23K | (m) | (m) | (m) | 4.59× |
| 2019-03-31 | $134.90M | $27.42M | $20.78M | (m) | $2.78M | (m) | (m) | (m) | 4.92× |
| 2018-12-31 | $87.81M | $35.30M | $23.69M | (m) | $3.32M | (m) | (m) | (m) | 2.49× |
| 2018-09-30 | $93.60M | $28.00M | $19.40M | (m) | $2.83M | (m) | (m) | (m) | 3.34× |
| 2018-06-30 | $101.84M | $28.41M | $15.09M | (m) | $1.71M | (m) | (m) | (m) | 3.59× |
| 2018-03-31 | $123.84M | $51.38M | $37.51M | (m) | $5.15M | (m) | (m) | (m) | 2.41× |
| 2017-12-31 | $138.36M | $35.41M | $23.79M | (m) | $6.00M | (m) | (m) | (m) | 3.91× |
| 2017-09-30 | $154.59M | $33.36M | $23.28M | (m) | $6.24M | (m) | (m) | (m) | 4.63× |
| 2017-06-30 | $106.88M | $27.38M | $23.86M | (m) | $7.52M | (m) | (m) | (m) | 3.90× |
| 2017-03-31 | $106.78M | $40.00M | $22.90M | (m) | $9.86M | (m) | (m) | (m) | 2.67× |
| 2016-12-31 | $124.60M | $43.82M | $19.14M | (m) | $15.82M | (m) | (m) | (m) | 2.84× |
| 2016-09-30 | $140.23M | $41.37M | $23.25M | (m) | $17.46M | (m) | (m) | (m) | 3.39× |
| 2016-06-30 | $147.97M | $35.49M | $28.45M | (m) | $10.37M | (m) | (m) | (m) | 4.17× |
| 2016-03-31 | $160.60M | $33.40M | $41.62M | (m) | $11.15M | (m) | (m) | (m) | 4.81× |
| 2015-12-31 | $171.85M | $31.47M | $57.63M | (m) | $7.30M | (m) | (m) | (m) | 5.46× |
| 2015-09-30 | $184.07M | $18.28M | $85.47M | (m) | $10.97M | (m) | (m) | (m) | 10.07× |
| 2015-06-30 | $162.14M | $14.52M | $70.30M | (m) | $5.61M | (m) | (m) | (m) | 11.17× |
| 2015-03-31 | $87.33M | $8.16M | $26.15M | (m) | $3.30M | (m) | (m) | (m) | 10.70× |
| 2014-12-31 | $98.95M | $14.09M | $40.54M | (m) | $2.80M | (m) | (m) | (m) | 7.02× |
| 2014-09-30 | $104.64M | $8.93M | $70.67M | (m) | $1.62M | (m) | (m) | (m) | 11.72× |
| 2014-06-30 | $112.94M | $11.60M | $88.54M | (m) | $2.88M | (m) | (m) | (m) | 9.73× |
| 2014-03-31 | $121.68M | $15.64M | $98.77M | (m) | $2.70M | (m) | (m) | (m) | 7.78× |
| 2013-12-31 | $58.68M | $28.97M | $33.72M | (m) | $3.30M | (m) | (m) | (m) | 2.03× |
| 2013-09-30 | $57.85M | $20.44M | $33.07M | (m) | $10.57M | (m) | (m) | (m) | 2.83× |
| 2013-06-30 | $25.54M | $19.07M | $10.35M | (m) | $540.35K | (m) | (m) | (m) | 1.34× |
| 2013-03-31 | $30.32M | $15.98M | $20.09M | (m) | $1.03M | (m) | (m) | (m) | 1.90× |
| 2012-12-31 | $15.97M | $8.38M | $5.65M | (m) | $830.43K | (m) | (m) | (m) | 1.91× |
| 2012-09-30 | $16.93M | $11.28M | $4.59M | (m) | $481.45K | (m) | (m) | (m) | 1.50× |
| 2012-06-30 | $21.32M | $10.23M | $5.95M | (m) | $432.11K | (m) | (m) | (m) | 2.08× |
| 2012-03-31 | $26.94M | $13.01M | $11.13M | (m) | $876.73K | (m) | (m) | (m) | 2.07× |
| 2011-12-31 | $31.91M | $11.04M | $17.35M | (m) | $467.91K | (m) | (m) | (m) | 2.89× |
| 2011-09-30 | $32.73M | $9.70M | $25.30M | (m) | $426.95K | (m) | (m) | (m) | 3.37× |
| 2011-06-30 | $38.61M | $9.94M | $30.59M | (m) | $347.82K | (m) | (m) | (m) | 3.88× |
| 2010-12-31 | $22.88M | $6.44M | $20.00M | (m) | $32.89K | (m) | (m) | (m) | 3.55× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |